Sunday, Jul 12, 2020 | Last Update : 12:01 AM IST

109th Day Of Lockdown

Maharashtra2384611326259893 Tamil Nadu134226859151898 Delhi110921876923334 Gujarat40155281832023 Uttar Pradesh3509222689913 Karnataka3341813838545 Telangana3222419205339 Andhra Pradesh2723514393309 West Bengal2710917348880 Rajasthan2334417634499 Haryana2038114912297 Madhya Pradesh1720112679644 Assam15537984936 Bihar1503910991118 Odisha11956797273 Jammu and Kashmir92615567149 Punjab71404945183 Kerala6535370828 Chhatisgarh3526283514 Uttarakhand3305267246 Jharkhand3192217022 Goa203912078 Tripura177313241 Manipur14357930 Puducherry120061916 Himachal Pradesh110182510 Nagaland6733030 Chandigarh5234037 Arunachal Pradesh2871092 Mizoram2031430 Sikkim134710 Meghalaya113451
  Science   01 Apr 2020  Japan gives the go-ahead to test Fujifilm's anti-flu drug Avigan in fight against coronavirus

Japan gives the go-ahead to test Fujifilm's anti-flu drug Avigan in fight against coronavirus

AFP
Published : Apr 1, 2020, 2:37 pm IST
Updated : Apr 1, 2020, 2:37 pm IST

Trials in China have suggested Avigan could play a role in shortening the recovery time for patients infected with coronavirus.

Avigan will be administered for a maximum of 14 days to coronavirus patients between the age of 20 and 74 who have mild pneumonia, Fujifilm said. (Representative Image | Pixabay - Angelo Esslinger)
 Avigan will be administered for a maximum of 14 days to coronavirus patients between the age of 20 and 74 who have mild pneumonia, Fujifilm said. (Representative Image | Pixabay - Angelo Esslinger)

Tokyo: Japan's Fujifilm has begun clinical trials to test the effectiveness of its anti-flu drug Avigan in treating patients with the new coronavirus, after reports of promising results in China.

Trials in China have suggested Avigan could play a role in shortening the recovery time for patients infected with coronavirus.

"The trial will be conducted on 100 patients until the end of June," a company spokesman told AFP on Wednesday.

"We will collect data, analyse them and file for approval after that," he added.

The drug will be administered for a maximum of 14 days to coronavirus patients between 20 and 74 years old with mild pneumonia, the spokesman said.

The study excludes pregnant women due to side effects shown in animal testing, he added.

The phase three trial comes after Prime Minister Shinzo Abe said Saturday that the government "will begin the necessary process to formally approve (Avigan) as a treatment against the new coronavirus." China has already completed clinical trials on favipiravir, the main ingredient in Avigan, the country's ministry of science and technology said last month.

Two trials in the country found the drug shortened recovery time for patients, but Fujifilm was not involved in those programmes.

Avigan is currently approved for manufacture and sale in Japan as an antiviral drug for flu.

"It is expected that Avigan may potentially have an antiviral effect on the new coronavirus" given the way it works on the flu virus, Fujifilm said in a statement announcing the trial.

Researchers and companies around the world are racing to find a cure for the new coronavirus, with the focus on existing medicines such as anti-malaria and anti-HIV drugs.

Hydroxychloroquine and chloroquine to treat malaria have shown early promise against the COVID-19 illness in early studies in France and China.

But experts urge caution until bigger trials demonstrate their effectiveness. The use of Hydroxychloroquine in particular has led to the death of a person in Assam, India, while three Nigerians overdosed on the drug hoping to prevent coronavirus infection.

Medical researchers around the world are also working to find a vaccine for the virus.

Tags: coronavirus (covid-19), fujifilm, flu symptoms, pneumonia, coronavirus drug trial